FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationCenter for Drug Evaluation and Research
 HHS Logo links to Department of Health and Human Services website

FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER

horizonal rule
CDER Home About CDER Drug Information Regulatory Guidance CDER Calendar Specific Audiences CDER Archives
 
Powered by Google
 

Drug Safety Oversight Board Meeting
March 20, 2008 Public Summary

 

  • The acting Executive Director updated the Board on recent communications including Healthcare Professional Sheets and Public Health Advisories (PHAs) posted since the last meeting regarding the drugs:
    • Tiotropium bromide (marketed as Spiriva) and Formoterol fumarate (marketed as Foradil)
    • Hydrocodone (marketed as Tussionex Pennkinetic Extended Release Suspension)

The safety related communications listed above were announced through MedWatch, CDER’s audio Podcasts and under News from CDER on CDER's home page.

  • The Board discussed the development of a pilot program for sharing and exchanging safety communications with other government healthcare organizations. 
  • The Board heard an update on the status of heparin. 
  • Finally, the Board reviewed data from and discussed issues on communicating information about a recently completed chemoprevention trial.

    back arrow DSOB Meeting Summaries

 

PDF document PDF requires the free Adobe Acrobat Reader

Date created: May 2, 2008

horizonal rule

CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | Privacy | Accessibility | HHS Home Page

FDA/Center for Drug Evaluation and Research